Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | DTYMK | P23919 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26099704 | 0.93 | TSHR (0.51) | TSHRTDP1L3MBTL1CES2CES1 | |
| SCHEMBL2240615 | 0.86 | TSHR (0.51) | TSHRTDP1L3MBTL1CES2CES1 | |
| SCHEMBL1225933 | 0.86 | TSHR (0.44) | TSHRTDP1CES2CES1ALDH1A1 | |
| SCHEMBL8129334 | 0.85 | TSHR (0.58) | TSHRTDP1L3MBTL1CES2CES1 | |
| SCHEMBL8136865 | 0.85 | TSHR (0.58) | TSHRTDP1L3MBTL1CES2CES1 | |
| SCHEMBL15938731 | 0.85 | ALDH1A1 (0.45) | TSHRTDP1CES2CES1ALDH1A1 | |
| SCHEMBL28521194 | 0.85 | TSHR (0.42) | TSHRTDP1CES2CES1ALDH1A1 | |
| SCHEMBL4180430 | 0.84 | TSHR (0.61) | TSHRTDP1L3MBTL1CES2CES1 | |
| SCHEMBL670578 | 0.84 | DTYMK (0.46) | TSHRTDP1DTYMKALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL11774750 | 0.82 | TSHR (0.59) | TSHRTDP1L3MBTL1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4606803-A1 | KRAS G12D DEGRADATION AGENT, AND PREPARATION METHOD AND USE THEREFOR | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. (CN) | 2025-08-27 | — | — | EP | disclosed |
| US-20250197369-A1 | NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SOOKMYUNG WOMEN'S UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2025-06-19 | — | — | US | disclosed |
| CN-119954709-A | Preparation method of sulfoxide compound, aniline compound and preparation method of aniline compound | 帕潘纳(北京)科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025056518-A1 | 5,6-DISUBSTITUTED ALKYL 1H AND 2H-INDAZOLES AS DUAL BUTYRYLCHOLINESTERASE AND p38α MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | UNIVERZA V LJUBLJANI (SI) | 2025-03-20 | — | — | WO | disclosed |
| US-20250042901-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2025-02-06 | — | — | US | disclosed |
| EP-4494640-A1 | NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Sookmyung Women's University Industry-Academic Cooperation Foundation (KR) | 2025-01-22 | — | — | EP | disclosed |
| CN-119212701-A | Novel histone deacetylase heterocycle inhibitor and pharmaceutical composition containing the same | 淑明女子大学校 产学协力团 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024259328-A1 | INHIBITORS OF RIPK2 AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-12139484-B2 | Substituted benzamides as RIPK2 inhibitors for treatment of inflammatory bowel disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| WO-2024083258-A1 | KRAS G12C DEGRADATION AGENT, AND PREPARATION METHOD AND USE THEREFOR | 上海领泰生物医药科技有限公司 | 2024-04-25 | — | — | WO | disclosed |
| EP-1997809-A2 | Indazole, benzoxazole and pyrazolopyridine derivatives for medical use | Array Biopharma Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1606283-B1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2004078116-A9 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2008-09-12 | — | — | WO | disclosed |
| EP-1606283-A4 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-05-23 | — | — | EP | disclosed |
| US-7135575-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1606283-A2 | P38 INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. | 2004-09-30 | — | — | US | disclosed |
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004078116-A2 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040176325-A1 | P38 MAP kinase inhibitors comprising indazole derivatives; antiinflammatory and antiproliferative agents; autoimmune, bone, and neurodegenerative disorders; viricides, infections | ARRAY BIOPHARMA INC. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197369-A1 | NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HDAC1, HDAC6, HDAC5 | TSHR 3854/4885TDP1 1096/4885L3MBTL1 3784/4885 |
| US-20040176325-A1 | P38 MAP kinase inhibitors comprising indazole derivatives; antiinflammatory and antiproliferative agents; autoimmune, bone, and neurodegenerative disorders; viricides, infections | MAPK1, MAPK3, MAP3K1 | TSHR 3672/4885TDP1 391/4885L3MBTL1 2820/4885 |
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | TSHR 3869/4885TDP1 803/4885L3MBTL1 2303/4885 |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | TSHR 3869/4885TDP1 803/4885L3MBTL1 2303/4885 |
| US-20250042901-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | TSHR 3274/4885TDP1 1175/4885L3MBTL1 3517/4885 |
| US-12139484-B2 | Substituted benzamides as RIPK2 inhibitors for treatment of inflammatory bowel disease | RIPK2, RIPK4, RIPK1 | TSHR 4407/4885TDP1 2595/4885L3MBTL1 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.